Document Type
Article
Publication Date
12-1-2023
Original Citation
Knorr K,
Rahman J,
Erickson C,
Wang E,
Monetti M,
Li Z,
Ortiz-Pacheco J,
Jones A,
Lu S,
Stanley R,
Baez M,
Fox N,
Castro C,
Marino A,
Jiang C,
Penson A,
Hogg S,
Mi X,
Nakajima H,
Kunimoto H,
Nishimura K,
Inoue D,
Greenbaum B,
Knorr D,
Ravetch J,
Abdel-Wahab O.
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nat Cancer. 2023;4(12):1675-92.
Keywords
JGM, Humans, Antibodies, Monoclonal, Antigens, Surface, Leukemia, Myeloid, Acute, Receptors, Fc, Receptors, IgG, Ribonucleoproteins, Small Nuclear, Tumor Microenvironment
JAX Source
Nat Cancer. 2023;4(12):1675-92.
ISSN
2662-1347
PMID
37872381
DOI
https://doi.org/10.1038/s43018-023-00656-2
Abstract
Despite recent advances in the treatment of acute myeloid leukemia (AML), there has been limited success in targeting surface antigens in AML, in part due to shared expression across malignant and normal cells. Here, high-density immunophenotyping of AML coupled with proteogenomics identified unique expression of a variety of antigens, including the RNA helicase U5 snRNP200, on the surface of AML cells but not on normal hematopoietic precursors and skewed Fc receptor distribution in the AML immune microenvironment. Cell membrane localization of U5 snRNP200 was linked to surface expression of the Fcγ receptor IIIA (FcγIIIA, also known as CD32A) and correlated with expression of interferon-regulated immune response genes. Anti-U5 snRNP200 antibodies engaging activating Fcγ receptors were efficacious across immunocompetent AML models and were augmented by combination with azacitidine. These data provide a roadmap of AML-associated antigens with Fc receptor distribution in AML and highlight the potential for targeting the AML cell surface using Fc-optimized therapeutics.
Comments
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.